FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a humanised antibody which specifically binds to human complement factor Bb protein, to a composition, a conjugate and an injection device containing same, as well as to a method for production thereof. Also disclosed is a nucleic acid and a set of nucleic acids encoding said antibody, a vector and a set of vectors, as well as a cell containing them.
EFFECT: invention is effective for treating a complement-mediated disease or disorder in a subject, as well as for inhibiting complement pathway activity in a subject.
36 cl, 12 dwg, 15 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
